Ffa1 (gpr40) as a therapeutic target for neural angiogenesis diseases or disorders
AssigneeChildren's Medical Center Corporation
InventorsLois Smith, Jean-Sebastien Joyal
Life of this patent
Estimating the term…
Abstract
The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.
Claims13
A method for treating age-related macular degeneration (AMD) in a subject, the method comprising administering a FFA1 inhibitor to the subject.
A method for treating macular telangiectasia (MacTel) in a subject, the method comprising administering a FFA1 inhibitor to the subject.
(canceled)
A method for increasing glucose uptake in a retinal cell, the method comprising obtaining a retinal cell and contacting the retinal cell with a FFA1 inhibitor, thereby increasing glucose uptake in the retinal cell.
-25. (canceled)
Dependencies are inferred from the claim text.